Completed
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line
NCT05734053
- Conditions
- Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia, +11 more
- Locations
-
- Novartis Investigative Site Freudenstadt, Baden-Wurttemberg, Germany
- Novartis Investigative Site Aschaffenburg, Bavaria, Germany
- Novartis Investigative Site Augsburg, Bavaria, Germany
- Novartis Investigative Site Bayreuth, Bavaria, Germany